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INTRODUCTION
Viruses are responsible for a number of human pathogeneses 
including cancer. Several hard‑to‑cure diseases and complex 
syndromes including Alzheimer’s disease, type 1 diabetes, 
and hepatocellular carcinoma have been associated with viral 
infections.[1‑3] Moreover, due to increased global travel and 
rapid urbanization, epidemic outbreaks caused by emerging and 
re‑emerging viruses represent a critical threat to public health, 
particularly when preventive vaccines and antiviral therapies are 
unavailable. Examples include the recent emergence of dengue 
virus, influenza virus, measles virus, severe acute respiratory 
syndrome (SARS) virus, and West Nile virus outbreaks.[4‑6] To 
date, however, many viruses remain without effective immu‑
nization and only few antiviral drugs are licensed for clinical 
practice. The situation is further exacerbated by the potential 
development of drug‑resistant mutants, especially when using 
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viral enzyme‑specific inhibitors, which significantly hampers 
drug efficacy.[7‑10] Hence, there is an urgent need to discover novel 
antivirals that are highly efficacious and cost‑effective for the 
management and control of viral infections when vaccines and 
standard therapies are lacking.
Herbal medicines and purified natural products provide a rich 
resource for novel antiviral drug development. Identification of 
the antiviral mechanisms from these natural agents has shed light 
on where they interact with the viral life cycle, such as viral entry, 
replication, assembly, and release, as well as on the targeting of 
virus–host‑specific interactions. In this brief report, we sum‑
marize the antiviral activities from several natural products and 
herbal medicines against some notable viral pathogens including 
coronavirus (CoV), coxsackievirus (CV), dengue virus (DENV), 
enterovirus 71 (EV71), hepatitis B virus (HBV), hepatitis C 
virus (HCV), herpes simplex virus, human immunodeficiency 
virus (HIV), influenza virus, measles virus (MV), and respiratory 
syncytial virus (RSV) [Table 1].
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Table 1. Antiviral effects from several natural products and herbal medicines against specific viruses.
Virus Natural product(s) evaluated Proposed mechanism(s) References
Coronavirus Saikosaponins (A, B2, C, D) against HCoV‑22E9 Saikosaponin B2 inhibits viral attachment and 
penetration stages
[14]
Lycoris radiata and its active component 
lycorine, Artemisia annua, Pyrrosia lingua, and 
Lindera aggregata against SARS‑CoV
Unclear [15]
Phenolic compounds of Isatis indigotica against 
SARS‑CoV
SARS‑CoV 3CL protease inhibitor [16]
Amentoflavone isolated from Torreya nucifera 
against SARS‑CoV
SARS‑CoV 3CL protease inhibitor [17]
Myricetin and scutellarein against SARS‑CoV SARS‑CoV helicase inhibitor [18]
Houttuynia cordata water extract against 
SARS‑CoV
SARS‑CoV 3CL protease inhibitor; viral 
polymerase inhibitor
[19]
Coxsackievirus Aqueous and ethanolic extracts of Ocimum 
basilicum as well as its component compounds 
linalool, apigenin, and ursolic acid against CVB
Ursolic acid interferes with viral infection and 
replication
[21]
Raoulic acid from Raoulia australis against CVB Unclear [22]
Herbal prescription Xiao‑Chai‑Hu‑Tang against 
CVB
Induction of type I interferon response [23]
Bupleurum kaoi against CVB Induction of type I interferon response [24]
Dengue virus Baicalein against DENV‑2 Virucidal activity against extracellular virus; 
impedes viral adsorption onto the host cell; 
inhibits viral replication post entry
[28]
Quercetin against DENV‑2 Inhibits viral replication but not the viral 
attachment and entry processes
[29]
Narasin against DENV‑2 Disrupts viral protein synthesis without 
affecting viral RNA replication
[30]
Marine seaweed extracts against DENV serotypes 
1–4; Canistrocarpus cervicornis, Padina 
gymnospora, Palisada perforate, and Caulerpa 
racemosa are most effective
Act at the early stage of viral infection [31]
Chebulagic acid and punicalagin isolated from 
Terminalia chebula Retz. against DENV‑2
Inactivate free virus particles and inhibit early 
viral entry including attachment and penetration 
phases; do not affect viral cell‑to‑cell 
transmission
[32]
Enterovirus 71 Aqueous and ethanolic extracts of Ocimum 
basilicum as well as its component compounds 
linalool, apigenin, and ursolic acid
Ursolic acid inhibits viral infection and 
replication
[21]
Raoulic acid from Raoulia australis Unclear [22]
Gallic acid from Woodfordia fruticosa flowers Unclear [36]
Epigallocatechin gallate from green tea Interferes with viral replication via modulation 
of the cellular redox environment
[37]
Hepatitis B virus Isochlorogenic acid A from Laggera alata Unclear [46]
Amide alkaloid from Piper longum Unclear [47]
Dehydrocheilanthifoline isolated from Corydalis 
saxicola
Unclear [48]
Herbal prescription Xiao‑Chai‑Hu‑Tang Inhibits the production of HBV and the 
expression of HBeAg
[49]
Saikosaponins (C, D) from Bupleurum species Saikosaponin C inhibits HBeAg expression and 
HBV DNA replication
[50]
Ethanol extract from Polygonum cuspidatum 
Sieb. et Zucc.
Unclear [51]
Curcumin Viral transcription suppressor via 
down‑regulation of the coactivator PGC‑1α
[52]
Hepatitis C virus Standardized extracts of Silybum marianum Antiviral effect partly due to enhancement of 
the IFN‑associated JAK‑STAT pathway
[55]
Flavonolignans from Silybum marianum/
silymarin
Antiviral effect probably related to antioxidant 
functions of the flavonolignans
[56]
Curcumin HCV replication inhibitor via suppressing 
Akt‑SREBP‑1 pathway
[60]
Contd...
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Table 1. Contd...
Virus Natural product(s) evaluated Proposed mechanism(s) References
Inhibits viral entry by affecting the fluidity of 
the HCV envelope
[61]
Epigallocatechin‑3‑gallate Inhibits viral entry [62,63]
Griffithsin Prevents infection and inhibits viral cell‑to‑cell 
transmission
[64,65]
Ladanein Inhibits viral entry [66]
Tellimagrandin I from Rosae Rugosae Flos. HCV invasion inhibitor [67]
Chebulagic acid and punicalagin isolated from 
Terminalia chebula Retz.
Inactivate free virus particles; interfere with 
viral binding, fusion, and post‑infection 
cell‑to‑cell spread
[32]
Herpes simplex 
virus
ent‑Epiafzelechin‑(4α→8)‑epiafzelechin isolated 
from Cassia javanica against HSV‑2
Inhibits viral replication [72]
Herbal prescription Long‑Dan‑Xie‑Gan‑Tan 
against HSV‑1 and HSV‑2
Inactivation of virus particles [73]
Herbal prescription Yin‑Chen‑Hao‑Tang against 
HSV‑1 and HSV‑2
Inactivation of virus particles [74]
Hippomanin A isolated from Phyllanthus urinaria 
against HSV‑2
Unclear [75]
Geraniin and 1,3,4,6‑tetra‑O‑galloyl‑β‑D‑glucose 
isolated from Phyllanthus urinaria against HSV‑1 
and HSV‑2
Unclear [76]
Excoecarianin isolated from Phyllanthus urinaria 
against HSV‑2
Inactivation of virus particles [77]
Chebulagic acid and punicalagin isolated from 
Terminalia chebula Retz. against HSV‑1
Cell surface GAG‑competitors; inhibit viral 
entry (binding and fusion) and post‑infection 
cell‑to‑cell spread
[78]
Meliacine derived from Melia azedarach against 
HSV‑2 infection in a mouse model
Induces TNF‑α and IFN‑γ production [81]
Houttuynoids A‑E from Houttuynia cordata 
against HSV‑1
Unclear [82]
Aqueous extract from Rhododendron 
ferrugineum L. against HSV‑1
Inhibits viral adsorption and penetration [83]
Blackberry extract against HSV‑1 Inhibits viral replication and exhibits virucidal 
activity
[84]
Proanthocyanidin‑enriched extract from 
Myrothamnus flabellifolia Welw. against HSV‑1
Inhibits viral adsorption and penetration steps [85]
Glucoevatromonoside from Digitalis lanata 
against HSV‑1
Inhibits viral protein synthesis [86]
Human 
immunodeficiency 
virus
Artemisia annua and Artemisia afra against 
HIV‑1
Unclear [102]
Tricyclic coumarin from stem bark of 
Calophyllum brasiliense against HIV‑1
Inhibits viral replication in both acute and 
chronic infections by suppressing NF‑κB 
activation
[105]
Melittin against HIV‑1 Inactivates virus through disruption of the viral 
lipid envelope
[106]
Influenza virus Elderberry liquid extract from Sambucus nigra 
against IFA and IFB
Unclear [115]
Extract from Pelargonium sidoides roots against 
IFA
Inhibits viral entry and release; inhibits viral 
hemagglutination and NA activity
[116]
Aqueous extract from dandelion (Taraxacum 
officinale) against IFA
Inhibits viral NP RNA levels and polymerase 
activity
[117]
Spirooliganone B from the roots of Illicium 
oligandrum against IFA
Unclear [118]
Chalcones from Glycyrrhiza inflate against IFA IFA NA inhibitors [120]
Xanthones from Polygala karensium against IFA IFA NA inhibitors [121]
Homoisoflavonoids from Caesalpinia sappan 
against IFA
IFA NA inhibitors [122]
Contd...
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CORONAVIRUS
CoV is an enveloped, positive‑sense single‑stranded RNA (ss‑
RNA) virus belonging to the Coronaviridae family. The CoV 
family consists of several species and causes upper respiratory 
tract and gastrointestinal infections in mammals and birds. In 
humans, it mainly causes common cold, but complications in‑
cluding pneumonia and SARS can occur.[11] The known human 
CoV (HCoV) includes HCoV‑229E, ‑OC43, ‑NL63, ‑HKU1, 
and the more widely known severe acute respiratory syndrome 
coronavirus (SARS‑CoV) which caused a global threat with 
high mortality in 2003.[12] In 2012, the World Health Organiza‑
tion (WHO) designated a sixth type of HCoV infection identified as 
the Middle East respiratory syndrome coronavirus (MERS‑CoV) 
which is associated with high fatality.[13]
There are no specific treatments for CoV infection and pre‑
ventive vaccines are still being explored. Thus, the situation 
reflects the need to develop effective antivirals for prophylaxis 
and treatment of CoV infection. We have previously reported 
that saikosaponins (A, B2, C, and D), which are naturally occur‑
ring triterpene glycosides isolated from medicinal plants such 
as Bupleurum spp. (柴胡 Chái Hú), Heteromorpha spp., and 
Scrophularia scorodonia (玄參 Xuán Shēn), exert antiviral ac‑
tivity against HCoV‑22E9.[14] Upon co‑challenge with the virus, 
these natural compounds effectively prevent the early stage of 
HCoV‑22E9 infection, including viral attachment and penetration. 
Extracts from Lycoris radiata (石蒜 Shí Suàn), Artemisia annua 
(黃花蒿 Huáng Huā Hāo), Pyrrosia lingua (石葦 Shí Wěi), and 
Lindera aggregata (烏藥 Wū Yào) have also been documented to 
display anti–SARS‑CoV effect from a screening analysis using hun‑
dreds of Chinese medicinal herbs.[15] Natural inhibitors against the 
SARS‑CoV enzymes, such as the nsP13 helicase and 3CL protease, 
have been identified as well and include myricetin, scutellarein, 
and phenolic compounds from Isatis indigotica (板藍根 Bǎn Lán 
Gēn) and Torreya nucifera (榧 Fěi).[16‑18] Other anti‑CoV natural 
medicines include the water extract from Houttuynia cordata 
(魚腥草 Yú Xīng Cǎo), which has been observed to exhibit several 
antiviral mechanisms against SARS‑CoV, such as inhibiting the 
viral 3CL protease and blocking the viral RNA‑dependent RNA 
polymerase activity.[19]
Table 1. Contd...
Virus Natural product(s) evaluated Proposed mechanism(s) References
Measles virus Herbal prescription Sheng‑Ma‑Ge‑Gen‑Tang Antiviral effect may be modulated by TNF‑a 
stimulation
[129]
Cherokee remedy spicebush Unclear [130]
Biflavonoids from Rhus succedanea and Garcinia 
multiflora, as well as their methyl ethers and 
acetates
Unclear [131]
Calcium spirulan from the blue‑green alga 
Spirulina platensis
Unclear [132]
Crotolus durissus terrificus snake venom Probably virucidal or targets viral entry [133]
Extracts of Zanthoxylum chalybeum and 
Warburgia ugandensis
Unclear [135]
Olinia rochetiana (Olkirenyi) and Warburgia 
ugandensis (Osokonoi)
Neutralize virus particles [137]
Stem and root extract of Cajanus cajan Unclear [138]
Chebulagic acid and punicalagin isolated from 
Terminalia chebula Retz.
Inactivate free virus particles; interfere with 
viral binding, fusion, and post‑infection 
cell‑to‑cell spread
[32]
Respiratory 
syncytial virus
Chebulagic acid and punicalagin isolated from 
Terminalia chebula Retz.
Inactivate free virus particles and inhibit early 
viral entry including attachment and penetration 
phases; do not affect viral cell‑to‑cell 
transmission
[32]
Uncinoside A and B from Selaginella uncinata Unclear [148]
Genkwanol B, genkwanol C, and stelleranol 
extracted from Radix Wikstroemiae
Unclear [149]
Flavones from the leaves of Lophatherum gracile Unclear [150]
Herbal prescription Sheng‑Ma‑Ge‑Gen‑Tang Inhibits viral attachment and internalization 
steps; stimulates IFN‑β secretion
[151]
Cimicifuga foetida L. Inhibits viral attachment and internalization 
steps; stimulates IFN‑β secretion
[152]
Cimicifugin from Cimicifuga foetida L. Inhibits viral attachment and internalization 
steps; stimulates IFN‑β secretion
[153]
Resveratrol against RSV‑induced inflammation Reduces virus‑induced airway inflammation via 
down‑regulation of IFN‑γ levels during RSV 
infection
[154]
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COXSACKIEVIRUS
CV, including subgroups A (CVA) and B (CVB), is a member 
of the Picornaviridae family, and the non‑enveloped positive‑sense 
ssRNA virus is typically transmitted by fecal–oral route and contact 
with respiratory secretions. While the symptoms of infection can 
include mild illnesses such as fever, malaise, rashes, and common 
cold‑like presentation, more severe cases may result in diseases of 
the central nervous system, including aseptic meningitis, encepha‑
litis, and paralysis.[20] CVA is best known as one of the causative 
agents of hand, foot, and mouth disease (HFMD) in young children.
Unfortunately, there is no vaccine or specific antiviral therapy 
available to prevent CV infection or the diseases it causes. Never‑
theless, drugs discovered from natural products, herbs, and tradi‑
tional decoctions have shown some promise for the development 
of therapeutics against CV infection. The aqueous extract, ethanolic 
extract, and bioactive compounds including linalool, apigenin, and 
ursolic acid from the popular culinary/medicinal herb Ocimum 
basilicum (sweet basil) (羅勒 Luó Lè) have been observed to pos‑
sess antiviral activity against CVB1.[21] In particular, ursolic acid 
interferes with CVB1 replication post‑infection.[21] Raoulic acid 
from Raoulia australis has also been reported as a potential antiviral 
agent against several CVB subtypes, but the mechanism of its effect 
is unclear.[22] In addition, we have previously reported that both the 
medicinal prescription Xiao‑Chai‑Hu‑Tang (小柴胡湯 Xiǎo Chái 
Hú Tang) and its major component herb Bupleurum kaoi (柴胡 Chái 
Hú) inhibit CVB1 infection via the induction of type I interferon 
response.[23,24] This finding suggests that type I interferon inducers 
may be helpful in controlling CVB infection and could be further 
explored as a treatment strategy.
DENGUE VIRUS
DENV is an enveloped positive‑sense ssRNA virus of the 
Flaviviridae family. As a prominent arbovirus in Southeast Asia, 
DENV is transmitted by mosquito bites, typically by Aedes ae-
gypti.[25] Four serotypes of the virus exist (DENV1 − 4) and all can 
cause dengue fever.[26] Clinical manifestations of DENV infection 
can include inapparent/mild febrile presentation, classical dengue 
fever (fever, headache, myalgias, joint pains, nausea, vomiting, and 
skin rash), and life‑threatening hemorrhagic diseases, specifically 
dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) 
in severe cases.[27]
Despite being an old disease, current immunization and thera‑
peutic options available for prevention and control of DENV infec‑
tion are severely limited. Management of dengue‑associated dis‑
eases consists of preventing the viral infection by mosquito control 
and relieving symptoms in the infected individuals. Development 
of prophylactic/therapeutic treatment against DENV infection us‑
ing natural products may help address some of these current limi‑
tations. The flavone baicalein, for example, exerts potent activity 
against DENV adsorption to the host and post‑entry viral replica‑
tion.[28] In addition, several natural products such as quercetin and 
narasin, as well as marine seaweed extracts have been observed 
to possess significant anti‑DENV properties.[29‑31] Recently, we 
have reported chebulagic acid and punicalagin, two hydrolys‑
able tannins isolated from Terminalia chebula (訶子 Hē Zǐ), 
as broad‑spectrum antiviral agents against several viruses includ‑
ing DENV.[32] Specifically, chebulagic acid and punicalagin can 
directly inactivate free DENV particles and interfere with the 
attachment and fusion events during early viral entry. Identifica‑
tion of these natural viral inhibitors could help the development 
of therapeutics against DENV infection and reduce the risks of 
DHF/DSS.
ENTEROVIRUS 71
EV71 is a member of the Picornaviridae family, possessing 
a positive‑sense ssRNA genome and is non‑enveloped. EV71 is 
ordinarily transmitted by fecal–oral route, but transmission by 
respiratory droplet is also possible. It is one of the major causes of 
HFMD in children, is sometimes associated with severe neurologi‑
cal diseases, and can be fatal.[20] The transmission rate in children 
under 5 years of age is typically high in endemic areas and several 
outbreaks have occurred over the past few decades.[33‑35]
Medication and preventive vaccines against EV71 are pres‑
ently in development and palliative care is used to ameliorate 
the symptoms. Nevertheless, several natural products and herbal 
medicines have been shown to possess inhibitory activity against 
EV71 infection. Extracts and pure constituents of O. basilicum 
effectively block EV71 infection and replication.[21] In addition, 
raoulic acid, which has previously been mentioned as an inhibitor 
to CVB, also suppresses EV71.[22] Gallic acid from Woodfordia 
fruticosa flowers (蝦子花 Xiā Zǐ Huā) has also been observed to 
exert anti‑EV71 activity.[36] Finally, epigallocatechin gallate from 
green tea has been identified to interfere with EV71 replication via 
modulation of the cellular redox environment.[37] Without efficient 
medical treatment for the prevention and control of infection by 
EV71, further studies in identifying novel antivirals against the 
enterovirus are encouraged.
HEPATITIS B VIRUS
HBV is the prototype virus of the Hepadnaviridae family. 
It is an enveloped virus possessing a relaxed circular, partially 
double‑stranded DNA (dsDNA) genome.[38] HBV causes hepatitis 
B and the infection is transmitted by exposure to blood or body 
fluids containing the virus. Although spontaneous recovery is com‑
mon following acute hepatitis B, medication is recommended for 
chronic infection because of the risk of developing cirrhosis and 
hepatocellular carcinoma (HCC). The development of HBV vac‑
cine and nationwide hepatitis B vaccination program in endemic 
countries such as Taiwan have helped control HBV infection as 
well as reduce the incidence of childhood HCC.[39]
Despite the existence of preventive vaccines, the present 
HBV‑infected population, including those in areas where vacci‑
nation program is unavailable, remains at risk for end‑stage liver 
diseases. Therapeutic treatment against HBV includes nucleotide/
nucleoside analogs such as lamivudine, adefovir, tenofovir, telbi‑
vudine, and entecavir, as well as the immune modulator pegylated 
interferon‑a (Peg‑IFN‑a).[40] However, eradication of HBV from 
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the host proves difficult once persistent infection is established, 
and the situation is further aggravated by risks of selecting 
drug‑resistant viral mutants, treatment failure in non‑responders, 
and potential future viral reactivation. Therefore, anti‑HBV drug 
discovery is still a matter of importance for supporting current 
therapy and hepatitis B management program to treat some current 
300‑400 million carriers globally.[41]
Extensive studies have been conducted over the past few 
decades to identify anti‑HBV agents from natural products and 
herbal medicines, and some have been thoroughly covered else‑
where.[42‑45] As examples, isochlorogenic acid A from Laggera 
alata, amide alkaloid from Piper longum (假蒟 Jiǎ Jù), and 
dehydrocheilanthifoline from Corydalis saxicola have been 
reported for their anti‑HBV activities.[46‑48] We have also previ‑
ously demonstrated the antiviral effects of the herbal prescription 
Xiao‑Chai‑Hu‑Tang (小柴胡湯 Xiǎo Chái Hú Tang), the saikosa‑
ponins from Bupleurum species (柴胡 Chái Hú), and the ethanol 
extract from Polygonum cuspidatum sieb. et zucc (虎杖 Hǔ Zhàng) 
against HBV in vitro.[49‑51] Another example is curcumin, which 
has been shown to inhibit HBV gene replication and expression 
by down‑regulating the peroxisome proliferator‑activated receptor 
gamma coactivator 1‑alpha (PGC‑1a), the coactivator of HBV 
transcription.[52] As novel anti‑HBV inhibitory agents are being 
discovered, future studies should also evaluate potential combi‑
nation treatments with standard nucleotide/nucleoside analogs or 
IFN‑a‑based therapies for the management of hepatitis B.
HEPATITIS C VIRUS
HCV is an enveloped flavivirus possessing a positive‑sense 
ssRNA. Transmission of HCV mainly occurs by blood‑to‑blood 
contact, such as through intravenous injections, blood transfusion, 
and various exposures to blood contaminants (tattooing, piercing, 
razor and toothbrush sharing, etc.). Due to the highly mutable na‑
ture of HCV, a preventive vaccine is not yet available. About 70% 
of infections become persistent, resulting in an estimated 300 mil‑
lion carriers worldwide of which 1‑3% may progress to end‑stage 
liver diseases including cirrhosis and HCC.[53] The present standard 
of care consists of parenteral Peg‑IFN‑a plus oral ribavirin, and 
will soon incorporate the new protease inhibitors boceprevir and 
telaprevir for combination therapy. However, several obstacles 
remain in the current method of therapeutic treatment against HCV, 
including limited efficacy for certain viral genotypes, inevitable 
selection of drug‑resistant mutants, serious side‑effects, high cost 
of medication, patient adherence issues, and challenges in the 
difficult‑to‑treat populations such as non‑responders and liver 
transplant patients.[54] Thus, continuous development of anti‑HCV 
agents is necessary to meet these shortcomings.
Various natural products have been explored for their antiviral 
effects against HCV infection. Silybum marianum (also known as 
“Milk Thistle” or “silymarin”) and its flavonolignans have been 
demonstrated to exert anti‑HCV activity in vitro,[55,56] and several 
clinical evaluations have shown promising effects in reducing the 
viral load.[57‑59] Curcumin has been identified as a potential inhibitor 
of HCV replication, potentially by suppressing sterol regulatory 
element binding protein‑1 (SREBP‑1)‑Akt pathway,[60] and more 
recently its negative effect on HCV entry has been demonstrated.[61] 
Other natural compounds have been observed to prevent HCV en‑
try as well, and these include epigallocatechin‑3‑gallate, griffithsin, 
ladanein, and tellimagrandin I.[62‑67] Similarly, we have recently 
identified the hydrolyzable tannins chebulagic acid and punicalagin 
as potent inhibitors of HCV entry.[32] The two tannins inactivate 
free virus particles, prevent viral attachment and penetration into 
the host cell, and disrupt post‑infection cell‑to‑cell transmission 
of HCV. Since immunization against HCV is at present unavail‑
able, the discovery of novel anti‑HCV entry inhibitors could help 
develop preventive therapies/measures against hepatitis C.
HERPES SIMPLEX VIRUS
Herpes simplex virus type 1 and type 2 (HSV‑1 and HSV‑2) 
are enveloped dsDNA viruses belonging to the Herpesviridae 
family. HSV infection usually causes mucocutaneous lesions that 
occur in oral/perioral (typically by HSV‑1) and genital (commonly 
by HSV‑2) areas, as well as on other body sites. HSV causes 
lifelong infection by establishing itself in sensory neurons and 
can be reactivated by various stimuli including sunlight, fever, 
immunosuppression, menstruation, or stress.[68] Transmission of 
HSV results from contact with infected lesions and can occur via 
vertical transmission from infected mother to newborn. Although 
the disease is usually self‑limited and can be treated with anti‑
virals, severe complications can occur, particularly in neonates 
and immunosuppressed individuals, leading to risk of blindness 
with keratoconjunctivitis, and the potentially fatal meningitis and 
encephalitis.[69,70]
No vaccine is available against HSV and there are currently no 
drugs that can eradicate latent HSV infection. Although primary 
and recurrent infections can be controlled by nucleoside analogs 
such as acyclovir, penciclovir, and their prodrugs, the develop‑
ment of drug‑resistant virus is becoming a serious problem, espe‑
cially in immunocompromised patients.[71] Thus, identifying novel 
anti‑HSV agents that act with different mechanisms is crucial for 
clinical management of HSV. We have previously reported several 
natural products and herbal medicines that inhibit HSV infection 
and replication. For instance, ent‑epiafzelechin‑(4a→8)‑epiafzele
chin, extracted from Cassia javanica, inhibits HSV‑2 replication; 
the herbal prescriptions Long‑Dan‑Xie‑Gan‑Tan (龍膽瀉肝湯 
Lóng Dǎn Xiè Gān Tāng) and Yin‑Chen‑Hao‑Tang (茵陳蒿湯 
Yīn Chén Hāo Tang) both possess broad efficiency in diminishing 
HSV‑1 and HSV‑2 infectivity; hippomanin A, geraniin, 1,3,4,6‑tet‑
ra‑O‑galloyl‑beta‑d‑glucose, and excoecarianin isolated from Phyl-
lanthus urinaria (葉下珠 Yè Xià Zhū) can potently impede HSV 
infection.[72‑77] In addition, we have also identified the hydrolyzable 
tannins chebulagic acid and punicalagin as cell surface glycosami‑
noglycan (GAG) competitors that can inhibit HSV‑1 entry and 
cell‑to‑cell spread.[78] HSV‑1 and also a multitude of viruses employ 
GAGs as initial attachment receptors during infection of their host 
cell. Both chebulagic acid and punicalagin are observed to target 
HSV‑1 glycoproteins that interact with GAGs and, in turn, prevent 
their association with cell surface GAGs as well as subsequent bind‑
ing receptors.[78] This inhibitory effect is shown (1) against cell‑free 
virus, (2) during the viral attachment and fusion stages, and (3) in 
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the intercellular junction spread of HSV‑1, which is mediated by its 
glycoproteins. Thus, both tannins are demonstrated to be efficient 
entry inhibitors to HSV‑1 and similar effects have been observed 
on another herpesvirus, the human cytomegalovirus, as well as on 
several other viruses known to engage GAGs for entry.[32]
Besides the natural products and traditional decoctions men‑
tioned above, a plethora of other natural anti‑HSV agents have 
also been identified.[79,80] Meliacine derived from Melia azedarach 
is observed to stimulate tumor necrosis factor‑alpha (TNF‑a) and 
IFN‑γ production, and reduce HSV‑2 shedding with improve‑
ment of virus‑induced pathogenesis in a mouse vaginal model of 
herpetic infection.[81] Houttuynoids A‑E are flavonoids isolated 
from Houttuynia cordata (蕺菜 Jí Cài), which have been found 
to exhibit potent anti–HSV‑1 activity.[82] Similarly, the aqueous 
extract from Rhododendron ferrugineum L., blackberry extract, 
and proanthocyanidin‑enriched extract from Myrothamnus flabel-
lifolia Welw. have been reported to inhibit HSV‑1 infection.[83‑85] 
Another example is glucoevatromonoside, a cardenolide from 
Digitalis lanata, which has been suggested to alter cellular elec‑
trochemical gradient and block HSV‑1 and HSV‑2 propagation in 
cells.[86] In addition, natural products from the marine environment 
represent a whole biodiversity in which many algae and sponges 
have been observed to contain active metabolites with anti‑HSV 
activity.[87,88] The abundance of natural anti‑HSV agents discovered 
should provide novel pharmacological activities against the virus, 
which could be further explored for potential application in the 
management of HSV infections.
HUMAN IMMUNODEFICIENCY VIRUS
HIV is a lentivirus of the Retroviridae family. The enveloped 
virus is characterized by targeting of the immune cells for infec‑
tion, reverse transcription of its ssRNA genome, and integration 
into the host chromosomal DNA.[89] Transmission of HIV occurs 
via exchange of virus‑containing blood and body fluids, such as 
through sexual contact, sharing of contaminated needles/sharp 
instruments, childbirth, as well as breastfeeding.[90] HIV is the 
causative agent of acquired immunodeficiency syndrome (AIDS), 
which is a progressive failure of the immune system due to 
CD4+ T‑lymphocyte depletion that leads to manifestation of 
life‑threatening opportunistic infections and malignancies.[91] To 
date, AIDS has resulted in more than 25 million deaths and there 
are currently about 34 million HIV‑infected individuals with an 
estimated 2‑3 million newly diagnosed cases annually.[13]
Despite nearly 30 years of research since its discovery, at 
present there is no effective preventive vaccine or cure for HIV 
infection. The high antigenic diversity and multiple mechanisms 
that the virus employs to subvert recognition by the human im‑
mune system have made prophylactic/therapeutic management of 
HIV infection difficult.[92] Nevertheless, the development of the 
highly active antiretroviral therapy (HAART), which consists of a 
cocktail of nucleoside analog/non‑nucleoside reverse‑transcriptase 
inhibitors, has dramatically decreased the morbidity and mortality 
associated with HIV/AIDS.[93] However, there is still a pressing 
need for alternative treatment strategies against HIV infection due 
to drug resistance problems, treatment‑associated toxicity, patient 
adherence, and restricted accessibility in resource‑poor areas.[94‑96]
An exhaustive list of natural products has been evaluated 
for anti‑retroviral/anti‑HIV activity and recently reviewed.[97,98] 
Moreover, many marine natural products with anti‑HIV activities 
have also been identified in search of novel therapeutics against 
the AIDS virus.[99‑101] To briefly mention some examples, the 
crude extracts of Artemisia annua (黃花蒿 Huáng Huā Hāo) and 
Artemisia afra have recently been reported as potential anti‑HIV 
medicines.[102] The Calophyllum species is known to contain 
several coumarins that are observed to exert inhibitory effect 
against HIV.[103,104] More recently, a tricyclic coumarin derived 
from the stem bark of Calophyllum brasiliense has been shown to 
inhibit HIV replication in in vitro models by suppressing nuclear 
factor‑kappa B (NF‑κB) activation.[105] Another novel anti‑HIV 
agent is the small peptide melittin, which is the active compo‑
nent of bee venom. The nanoformulated melittin is demonstrated 
to possess robust efficiency in capturing and inactivating HIV 
particles by disrupting the viral lipid envelope.[106] Based on the 
discoveries made so far, the recent progress in identifying natural 
antivirals against HIV should yield potential novel therapeutics that 
could play an important role in overcoming the current urgency 
in anti‑HIV/AIDS therapies.
INFLUENZA VIRUS
The influenza A, B, and C viruses (IFA, IFB, and IFC) are 
enveloped, negative‑sense ssRNA viruses classified in the Or-
thomyxoviridae family. These viruses cause respiratory infection 
yielding symptoms that include fever, headache, sore throat, 
sneezing, and muscle and joint pains, and can develop into more 
severe and potentially fatal conditions such as pneumonia.[107,108] 
IFA (most epidemic) has a wide host range including birds and 
humans as well as other mammals, whereas IFB seems to natu‑
rally infect humans and IFC (less frequently encountered) can 
be isolated from humans and swine.[109] Influenza virus infection 
has produced considerable morbidity in humans. An estimated 
250,000‑500,000 deaths occur annually due to seasonal epidemics, 
and in major pandemics, this number has been observed to rise 
to some 20‑40 million deaths, as in the case of the 1918 H1N1 
Spanish Flu.[13]
Despite the availability of vaccines based on predicted circu‑
lating strains, influenza viruses are known to continuously evolve 
their hemagglutinin (HA) and neuraminidase (NA) envelope 
proteins.[110,111] This variation renders any preexisting circulating 
antibody from earlier exposure or immunization ineffective at 
neutralizing the virus, hence making the host vulnerable to infec‑
tion. Furthermore, potential risks of cross‑species transmission and 
host adaptation of influenza viruses between animals and humans 
resulting in highly pathogenic strains have also raised concerns.[112] 
Another issue is the widespread development of drug resistance, 
which has been observed with the first generation of anti‑influenza 
medications, specifically the M2 ion channel blockers amanta‑
dine and rimantadine.[113] Resistant strains against the currently 
approved neuraminidase inhibitors (which prevent the release of 
mature influenza viruses) including oseltamivir and zanamivir 
have also already appeared.[114] Due to the drug resistance prob‑
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lems, the rapid evolution of influenza viruses, and the occurrence 
of several recent outbreaks (e.g., H5N1, H1N1, H7N9),[13] more 
sophisticated antiviral strategies are urgently needed to prevent 
and control potential pandemics with emerging influenza strains.
Several natural products have been examined for their effects 
against influenza. Standardized elderberry (接骨木 Jiē Gǔ Mù; 
Sambucus nigra) liquid extract exerts in vitro antiviral effects 
against IFA, IFB, as well as respiratory bacterial pathogens.[115] 
A licensed commercial extract from Pelargonium sidoides roots 
inhibits the entry of IFA, impairs viral hemagglutination as well 
as neuraminidase activity, and improves the symptoms of influen‑
za‑infected mice.[116] The aqueous extract from dandelion (蒲公英 
Pú Gōng Yīng; Taraxacum officinale) impedes IFA infection and 
decreases its polymerase activity as well as the nucleoprotein (NP) 
RNA level.[117] Spirooliganone B from the roots of Illicium oligan-
drum exhibits potent anti‑IFA activities.[118] A multitude of second‑
ary plant metabolites have also been identified as potential influenza 
NA inhibitors,[119] and more recent ones include chalcones from 
Glycyrrhiza inflata,[120] xanthones from Polygala karensium,[121] 
and homoisoflavonoids from Caesalpinia sappan (蘇木Sū Mù).[122] 
Further exploration of these natural anti‑influenza agents for clinical 
application will help broaden the drug portfolio for prophylactic/
therapeutic treatment of potential flu epidemics or pandemics.
MEASLES VIRUS
MV is an enveloped, negative‑sense ssRNA virus of the 
Morbillivirus genus in the Paramyxoviridae family. MV causes 
measles, an acute infection of the respiratory system character‑
ized by fever, conjunctivitis, coughing, runny nose, nausea, and 
a generalized macular red rash over the body. Complications 
can occur leading to pneumonia and encephalitis, which can be 
potentially fatal.[123] Although highly contagious through contact 
of respiratory droplets or airborne aerosols, immunization against 
measles given as a three‑part MMR vaccine (measles, mumps, 
and rubella) has made MV infection relatively uncommon in 
developed countries. As recovery usually follows uncomplicated 
MV infection, there are currently no specific antiviral treatments 
for measles. Despite the existence of a successful vaccine against 
MV, the virus remains a major killer of children in developing 
countries.[124,125] Another serious problem is the re‑emergence of 
measles in vaccinated populations and in non‑immunized adults, 
as highlighted by outbreaks in recent years.[6,126,127] These issues 
emphasize MV’s medical importance and the need to develop 
suitable drug therapies.
Efforts have been made at identifying natural products 
that inhibit MV and include a number of East and South‑
east Asian traditional medicines,[128] the herbal decoction 
Sheng‑Ma‑Ge‑Gen‑Tang (升麻葛根湯 Shēng Má Gé Gēn 
Tang),[129] the Cherokee remedy spicebush,[130] plant biflavonoids 
isolated from Rhus succedanea (野漆 Yě Qī) and Garcinia mul-
tiflora,[131] calcium spirulan from the blue‑green alga Spirulina 
platensis,[132] Crotalus durissus terrificus snake venom,[133] and 
several Rwandan and Ugandan medicinal plant extracts,[134,135] 
among others previously reviewed.[136] In addition, several tra‑
ditional dietary herb additives of the Maasai, including Olinia 
rochetiana (Olkirenyi) and Warburgia ugandensis (Osokonoi), 
have been reported to inhibit MV infection in vitro.[137] Another 
example is the plant extracts of Cajanus cajan which have 
been recently suggested to possess anti‑MV activity, although 
the bioactive constituents remain elusive.[138] The two tannins 
chebulagic acid and punicalagin also show robust effects against 
MV infection, particularly by inactivating the virus particles, 
interrupting the binding and fusion phases during viral entry, 
and preventing post‑infection virus spread.[32] Chebulagic acid 
and punicalagin could, therefore, serve as potential entry in‑
hibitors to MV.
RESPIRATORY SYNCYTIAL VIRUS
RSV is an enveloped negative‑strand ssRNA virus of the 
Paramyxoviridae family. It is a ubiquitous pathogen and the 
leading cause of viral lower respiratory tract infection in infants 
and children.[139] Virtually all children become infected with RSV 
before the age of 2 years.[140] RSV infection typically results in 
mild symptoms in healthy adults, but can lead to bronchiolitis 
or pneumonia in infants and immunocompromised individuals. 
Moreover, infant RSV infection poses a potential risk for child‑
hood asthma.[141,142] Although RSV causes the most severe disease 
in young infants, it continues to plague humans throughout the 
course of a lifetime. Immunity to RSV is generally not sufficient 
to provide protection and, consequently, humans are prone to 
repeated reinfections[143‑145] which can be life‑threatening in the 
elderly or immunocompromised.[146,147]
Currently, immunization against RSV is unavailable, and 
the few therapies that exist for the treatment of RSV infections 
such as palivizumab (monoclonal antibody against RSV fusion 
protein) and ribavirin (nucleoside analogue) are only moderately 
effective or limited in efficacy. Thus, there is a need to develop 
novel antivirals for the management of RSV infections. Several 
plant‑derived natural products have been demonstrated to exhibit 
anti‑RSV activity. Uncinoside A and B, the two chromone gly‑
cosides isolated from Selaginella uncinata, potently inhibit RSV 
infection.[148] Three biflavonoids, namely genkwanol B, genkwanol 
C, and stelleranol, extracted from Radix Wikstroemiae, have been 
observed to display antiviral activity against RSV.[149] Several 
flavone 6‑C‑monoglycosides from the leaves of Lophatherum 
gracile (淡竹葉 Dàn Zhú Yè) have been shown to reduce RSV 
infection in cytopathic effect‑reduction assay.[150] We have previ‑
ously also identified several anti‑RSV natural medicines, including 
the herbal prescription Sheng‑Ma‑Ge‑Gen‑Tang (升麻葛根湯 
Shēng Má Gé Gēn Tang) which is used for treating respiratory 
diseases, its major component herb Cimicifuga foetida L. (升麻 
Shēng Má), as well as the plant‑associated bioactive compound 
cimicifugin.[151‑153] In addition, the broad‑spectrum antiviral activity 
that we have demonstrated for the hydrolyzable tannins chebulagic 
acid and punicalagin also includes antiviral effects against RSV 
infection.[32] Specifically, the two tannins can inactivate RSV par‑
ticles and also block viral entry‑related events, including binding 
and fusion. Interestingly, both chebulagic acid and punicalagin are, 
however, ineffective against RSV post‑infection spread, but could 
abrogate the same event in MV, which is another paramyxovirus.[32] 
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Besides targeting the viral infection, some natural products may 
help improve RSV‑induced respiratory tract symptoms, including 
airway inflammation. Resveratrol is one such example, which 
has been observed to down‑regulate IFN‑γ levels and prevent 
airway inflammation/hyperresponsiveness during RSV infection 
in mice, suggesting its applicability in reducing RSV‑induced 
airway symptoms.[154]
PROSPECTS AND CONCLUSION
As many viruses remain without preventive vaccines and 
effective antiviral treatments, eradicating these viral diseases ap‑
pears difficult. Nonetheless, natural products serve as an excellent 
source of biodiversity for discovering novel antivirals, revealing 
new structure–activity relationships, and developing effective 
protective/therapeutic strategies against viral infections. Many 
natural products and herbal ingredients are observed to possess 
robust antiviral activity and their discoveries can further help de‑
velop derivatives and therapeutic leads (e.g., glycyrrhetinic acid 
derivatives as novel anti‑HBV agents, acetoxime derivative from 
the Mediterranean mollusk Hexaplex trunculus as inhibitor against 
HSV‑1, and caffeic acid derivatives as a new type of influenza NA 
antagonist).[155‑157] Our discovery of chebulagic acid and punicala‑
gin being capable of inhibiting entry of several viruses due to their 
GAG‑competing properties could help develop broad‑spectrum 
antivirals for prevention and control of these viral pathogens. As 
many studies in this domain are only preliminary, further explora‑
tion in characterizing the bioactive ingredients, defining the under‑
lying mechanisms, as well as assessing the efficacy and potential 
application in vivo is encouraged in order to help develop effective 
antiviral treatments. Furthermore, additional studies should also 
examine the possibility of combination therapies with other natural 
agents or with standard therapeutics, as a multi‑target therapy 
may help reduce the risk of generating drug‑resistant viruses. We 
believe that natural products will continue to play an important 
role and contribute to antiviral drug development.
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